N/A N=212 Midlines and Thrombophlebitis
Catheter Infection · Catheter Thrombosis · Catheter Complications
Primary: Upper Extremity CR-UEVT — 7; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=410 Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery
Venous Thromboembolism
Primary: Number of Participants With Postoperative VTE Within 48 Hours After Surgery — 5; 3 participants — p=0.72
N/A N=238 Study of Effectiveness of Smaller Gauge Fenestrated Catheters for Use in IV Contrast Enhanced CT Scans
Contrast Enhanced Computed Tomography
Primary: Acceptable Image Quality — 100; 100; 100 percentage of participants
N/A N=149 Hub Cleansing to Prevent Hub Infection
Bacteremia
Primary: Number of Central Venous Catheter Hubs With Internal Contamination — 42; 18; 39; 14 contaminated hubs
Phase 4 N=100 Post-Operative Colonization Rates of Femoral Nerve Catheters Treated With Chlorhexidine-Impregnated Patch
Catheter Infections · Spinal Catheter (Epidural) (Subdural); Complications, Infection or Inflammation
Primary: Catheter Tip Colonization — 2; 3 participants
N/A N=12 Internal Jugular Vein Flow in the Sitting Position
Jugular Venous Flow
Primary: Internal Jugular Venous Flow — 0.04; 0.4; 0.04; 0.21 cm2
N/A N=16 Community Central Line Infection Prevention Trial
Infection
Primary: Total Number of Central Line Associated Blood Stream Infections (CLABSI) — 113; 84; 123; 109 infections
N/A N=50 Ultrasound-Guided Peripheral Venous Access Using AccuCath
Intravenous Access
Primary: First Attempt Success Rate — 17; 11 Participants
Phase 3 N=105 Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines
Upper Extremity Deep Vein Thrombosis · Central Venous Catheter Thrombosis · Cancer
Primary: Primary Feasibility Outcome - Number of Participants Recruited Per Month — 7.5; 2.0 Average enrolment rate/month/site
Phase 2 N=50 Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer
Adrenal Cortex Neoplasms
Primary: Percentage of Participants With a Partial or Complete Response — 4; 6 Percentage of participants
N/A N=134 Foley Catheter for Induction of Labor
Foley Catheterization · Induction of Labor · 5 French Stylette
Primary: Duration of Insertion Between Foley Catheter Groups With and Without a Stylette. — 1.72; 1.88; 6.55; 5.00 minutes — p=.70
N/A N=152 Complications Associated With Central Venous Access in the NSICU: PICC vs CVC
PICC · Central Venous Catheter · Central Line
Primary: Participants With Complications With Central Access Including Insertion — 14; 10 Participants — p=0.271
N/A N=360 Peripheral Catheter Pressure Ulcer Prevention in Pediatry : Use of Compresses Versus Standard Care
Pressure Ulcer
Primary: Pressure Ulcer of Grade >=1 on the National Pressure Ulcer Advisory Panel (NPUAP) Scale — 48; 94 Participants
Phase 3 N=360 Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Cerebral Vein Thrombosis · Deep Vein Thrombosis · Hematopoietic and Lymphoid Cell Neoplasm
Primary: CIF of Major or Clinically Relevant Non-major Bleeding Combined With Death as Competing Risk — 9.6; 13.5 proportion of participants — p=0.3117
N/A N=12 Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology
Bone Metastases · Musculoskeletal Cancer · Soft Tissue Sarcoma
Primary: DVT Incident Rate — 0; 0 Participants